The site will have a staff of 400 employees.
Ohio just got a new manufacturing site.
Amgen announced that it has opened a new manufacturing site in central Ohio.1 According to a press release, the new site is the company’s most advanced facility to date.
The facility, which is part of Amgen’s global operations network, is 3000-000-square-feet. It will employ a staff of 400 people and has been designed to be environmentally sustainable. Amgen has pledged to be carbon neutral for all of its operations by the year 2027.
In a press release, Amgen’s chairman and chief executive officer Robert A. Bradway said, “Our new facility, known as Amgen Ohio, was designed with the latest innovation and technology to deliver safe, reliable medicines for 'every patient, every time. As part of Amgen's global biomanufacturing network, Amgen Ohio will play an important role in helping us address serious disease around the world with our innovative biomedicines."
Ohio’s lt. governor Jon Husted also stated, “This new Ohio facility is a success story in advanced healthcare manufacturing and the Made-in-America supply chain we need to live and thrive. Winning this project for Ohio creates 400 high-paying jobs and a $40 million annual payroll, supporting families and further growing the Ohio economy."
This move is the latest move by a pharma company to increase its ability to produce and manufacture its own drugs. While this is not Amgen’s first manufacturing site, it is its most advanced site, which demonstrates the level of importance it has to the company. Based on recent moves across the pharma industry, it appears that pharma companies are starting to put a higher value on their manufacturing capabilities.
Several other companies have recently made moves to increase their manufacturing capabilities, more commonly through a merger or acquisition.
Pharmaceutical Executive recently reported that Novo Nordisk’s parent company, Novo Holdings, has entered into an agreement to purchase Catalent.2 As part of the deal, Novo Nordisk will then purchase three manufacturing sites that Novo Holdings will acquire from Catalent. The overall deal is for $16.5 billion.
The move is likely part of Novo Nordisk’s plan to increase its capabilities to produce Wegovy, a popular drug that has become known for its weight loss effects. The drug became popular after influencers touted its impact on social media, which greatly increased the demand for the drug. Unfortunately, Novo Nordisk has been unable to meet the demand, making the drug expensive and difficult to find.
Last year, Novo Nordisk had to take steps to limit the low-dose, entry level version of the drug in the United States. The company recently increased the supply, but it is still struggling to meet the overall demand. The Catalent purchase, once finalized, will potentially improve its ability to do so.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
MDMA Therapy for Mental Health Conditions: Do the Benefits Outweigh the Risks?
October 25th 2024Despite a recent FDA Complete Response Letter issued to Lykos for midomafetamine capsules for the treatment of post-traumatic stress disorder, experts believe that the future is bright for psychedelic drugs that treat mental health conditions.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.